1. Hypaconitine has anti-inflammatory activity.
2. Hypaconitine could inhibit CaM expression and Cx43 (Ser368) phosphorylation.
3. Hypaconitine has neuromuscular blocking action, the mechanism was attributed mainly to blocking of the nerve compound action potential.
1. Sinomenine exerts significant antinociceptive effects for neuropathic pain via GABAa-mediated mechanism.
2. Sinomenine shows a significant neuroprotective effects against both LPS- and MPP+-induced DA neurotoxicity, and that this protection is mediated through microglia.
3. Sinomenine inhibits cerebral water content and neurological deficit, can be used to treat Alzheimer's diseases as well as other diseases that involve neuroinflammation.
4. Sinomenium is widely used as an immunosuppressive drug for treating rheumatic and arthritic diseases via release of histamine, but other effects such as inhibition of prostaglandin, leukotriene and nitric oxide synthesis may also be involved.
1. Swertiamarin is an active compound isolated from Enicostemma littorale.
2. Swertiamarin possesses anti-hyperglycemic, anti-hyperlipidemic, anti-diabetic activity and enhances β cell regeneration which causes reversal of diabetes.
3. Swertiamarin possesses cytoprotective and immune reactivity abilities.
4. Swertiamarin derivatives, LMP-09-1 and -2 have a potent anti-adipogenic effect.